OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15
OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15
News
“InVivo Interim” InVivo (NVIV) President, CEO and CFO Frank Reynolds Resigns; Michael J. Astrue In As Interim CEO and Sean Moran in As Acting CFO
“InVivo Interim” InVivo (NVIV) President, CEO and CFO Frank Reynolds Resigns; Michael J. Astrue In As Interim CEO and Sean Moran in As Acting CFO […]
“Corporate Governance Gap” InVivo (NVIV) Delays Listing to National Securities Exchange “Postponed”; Amarantus BioScience (AMBS) DTC Chill Lifted. What is the Next Step for Corporate Governance in the Biotechnology Sector?
Recent challenges to biotechnology companies have been in the form of corporate governance issues, especially those undergoing rapid growth. Two companies in particular, InVivo (NVIV) […]
“SEC’s A Crowd” SEC Finally Issues Determination on Internet-Based Crowdfunding Platforms. How Will This Affect Fundraising?
One of the major obstacles of growth for Internet based Crowdfunding platforms in the U.S. has been the reaction of regulatory authorities. However, two “no-action […]
Editor’s Note, October 24, 2013
Dear Subscriber, In the coming weeks we will be providing short profiles of selected companies presenting at the 7th Annual OneMedForum in San Francisco on […]
ISTO’s Cell Therapies Can Revolutionize Treatment of Joint, Bone Injuries
ISTO Technologies, Inc.is both a regenerative medicine and orthopedics company developing innovative cartilage and bone regeneration products for spinal therapy, sports medicine and trauma. ISTO is currently focused on the development of cell-based cartilage platform technology that can be applied to repair and regenerate damaged cartilage in the knee and spinal disc.
Aridis Pharmaceuticals: Better Alternative to Traditional Antibiotics?
Aridis Pharmaceuticals is a private biotechnology company focusing on improved alternatives to traditional antibiotics for the treatment of pneumonia and Cystic Fibrosis in addition to a few other conditions.
“Regulatory Rush”-The SEC Lifts The Ban On General Solicitation
On July 10th, 2013 new changes to regulations regarding the general solicitation of securities was announced by the Securities and Exchange Commission as the enactment […]
The Fly on the Wall: Athersys Publishes Study on Increasing Survival of Organ Transplants With Stem Cells
Athersys (ATHX) is a clinical stage based biopharmaceutical company with an exponentially growing pipeline and an array of products in therapeutics to treat significant and life-threatening diseases.
PR Newswire: BioDelivery Sciences International Secures $20 Million in Debt Financing
A company to keep a look out for in the upcoming future is BioDelivery Sciences International (BDSI), a specialty pharmaceutical company with a platform of drug delivery technologies to develop, commercialize, and improve already proven applications of therapeutics.